From Biomarker to Mortality Signal: How 20,000 Glycomes Are Reshaping Our Understanding of Aging and Disease

Standard clinical diagnostics are largely designed to identify pathology after significant physiological decline has already occurred. Blood glucose elevations indicate diabetes only after pancreatic function is compromised. LDL cholesterol marks cardiovascular risk after arterial changes have begun. C-reactive protein (CRP) climbs during an active, acute immune response. By the time these conventional signals are elevated, the underlying biology has often been shifting toward disease for years, or even decades.

The emerging field of longevity medicine seeks biomarkers that can detect this shift earlier. However, many current aging clocks act merely as proxies, they measure biological shadows rather than the mechanisms driving the aging process itself.

A newly released preprint from Mijakovac, Butz, Vučković, and an international team led by Prof. Gordan Lauc proposes a different paradigm. By harmonising almost 20 years of glycomics data from 20,405 individuals across 42 independent studies, the authors demonstrate that the glycans attached to our antibodies do more than just correlate with age. They reveal a slow, systemic, pro-inflammatory drift that links varied chronic diseases, and associates with mortality risk independent of standard clinical panels, and responds measurably to specific interventions.

The paper, titled “The Immunoglobulin G Glycome: A Modifiable Biomarker and Functional Effector of Aging, Disease, and Mortality”, was posted to medRxiv in April 2026. It represents one of the largest unified analyses of the IgG glycome conducted to date and advances our understanding of inflammaging on several fronts.

The Functional Difference: Effectors, Not Just Bystanders

To understand why this study is a notable advancement, it is necessary to distinguish between a bystander biomarker and a functional effector. Many epigenetic clocks measure DNA methylation changes that correlate tightly with chronological age, but it is often unclear whether those specific methylation marks actually cause aging or simply happen alongside it.

The Immunoglobulin G (IgG) glycome is fundamentally different. Immunoglobulin G (IgG) is the most abundant antibody class in human blood, playing a primary role in regulating systemic inflammation.

These glycans physically modulate how IgG binds to downstream immune receptors (Fc gamma receptors). These glycans physically modulate how IgG binds to downstream immune receptors (Fc gamma receptors). Specific glycan configurations, such as those containing sialic acid (S), promote anti-inflammatory antibody activity and facilitate resolution of inflammation. Conversely, some glycans are highly pro-inflammatory, such as those lacking core fucose.

Therefore, the IgG glycome is not a passive observer of inflammation; it is the biochemical mechanism that dictates it. When the glycome shifts toward a pro-inflammatory state, it actively contributes to the systemic tissue damage that characterises aging.

A 15-Year Dataset, Standardised for the First Time

A historical bottleneck in glycoscience, and proteomics more broadly, has been methodological heterogeneity. Different laboratories utilize varying instruments, normalisation choices, and reporting standards. This introduces "batch effects" that make it nearly impossible to directly compare a lupus cohort analyzed in 2012 with a diabetes cohort analyzed in 2020.

The new study overcomes this limitation through an unprecedented harmonization effort. All 42 datasets, encompassing 19 diseases and four aging cohorts, were processed at a single facility (Genos Glycoscience Research Laboratory) between 2008 and 2025 using standardised UHPLC, LC–MS, or CGE workflows.

The disease groups span three broad categories:

• Autoimmune and alloimmune conditions: systemic lupus erythematosus, ulcerative colitis, Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, Sjögren’s disease, systemic sclerosis, Hashimoto’s thyroiditis, multiple sclerosis, and graft-versus-host disease.
• Cardiometabolic conditions: cardiovascular disease overall and its subtypes (coronary artery disease, heart failure, atrial fibrillation) as well as diabetes mellitus and type 2 diabetes.
• Other conditions: chronic obstructive pulmonary disease, allergic sensitisation, and colorectal cancer.

By comparing these against four established population cohorts (Vis, Korčula, ORCADES, TwinsUK), the researchers created a highly standardised framework. This scale and uniformity allow for the cleanest direct comparison of disease- and age-associated glycome profiles to date.

The Shared Signature: A Unified Theory of Inflammaging

A central and profound finding of the study is the consistency of the glycome pattern across diverse, seemingly unrelated diagnoses.

Across nearly all 19 diseases, agalactosylated (G0) glycans were elevated, while galactosylated (G) and sialylated (S) glycans were reduced. Bisecting GlcNAc structures, also linked to pro-inflammatory IgG function, were higher in many conditions.

This specific compositional shift exactly mirrors chronological aging. The four aging cohorts demonstrated an identical directional change. Consequently, the glycome of a patient with diseases such as rheumatoid arthritis, type 2 diabetes, heart failure, or colorectal cancer resembles the glycome of an individual who is biologically older than their chronological age.

This advances our understanding of chronic disease by highlighting a shared biological substrate. The specific disease diagnosis may be less critical than understanding the duration and extent of biological pressure on the immune system. The data suggests that many chronic conditions are, at their core, manifestations of accelerated immune aging.

Quantifying the Burden: GlycanAge in Disease

To quantify this shift, the authors applied the GlycanAge algorithm, a biomarker derived from G0, G2, and S IgG glycans that estimates biological age from glycome composition.

GlycanAge was elevated relative to controls in nearly every disease examined. In autoimmune diseases, patients were on average 2.1 glycan years older than matched healthy controls. Acceleration was also observed in heart failure, colorectal cancer, type 2 diabetes, and diabetes mellitus. The effect was most pronounced in conditions with a systemic inflammatory component and less evident in conditions where systemic inflammation is less central (such as atrial fibrillation or allergic sensitisation in children).

The Mortality Finding: Capturing the Hidden Risk

Perhaps the most consequential contribution of this research is the survival analysis. The authors demonstrated that IgG glycans associate with incident death over time, independent of conventional clinical risk factors.

In the German Chronic Kidney Disease (GCKD) discovery cohort (4,827 participants; median follow-up 8.5 years; 840 deaths), each additional year of GlycanAge was associated with a 10 percent increase in the hazard of all-cause mortality in a model adjusted for chronological age and sex.

Crucially, after full adjustment for BMI, smoking, systolic blood pressure, LDL cholesterol, CRP, diabetes status, eGFR, and the urine albumin-to-creatinine ratio, the effect remained significant at a 5 percent increase per GlycanAge year.

The association of glycan age and mortality was successfully replicated in the Vis cohort after adjusting for all established risk factors except the inflammatory biomarker CRP further demonstrating the role of IgG glycans in inflammation. However, in the larger discovery cohort the association of glycan age with increased risk of all-cause mortality remained strong even after the inclusion of CRP. Although CRP is an established marker of systemic inflammation it predominantly reflects the acute-phase response limiting its ability to capture long-term inflammatory burden which may be more accurately reflected by IgG glycans that are less sensitive to transient inflammatory exposures. Maybe you can incorporate this text into the existing paragraph so the report of the results is accurate but the message is still the same.

A Modifiable Biomarker for Proactive Medicine

A clinically useful biomarker of aging must do more than predict poor outcomes; it must respond to interventions. The authors evaluated this using three distinct, mechanistically varied approaches:

• Hormone replacement therapy (HRT): Menopause is associated with accelerated glycan aging, driven by the loss of estrogen's immunomodulatory effects. In 19 perimenopausal and menopausal women initiating body-identical HRT, glycan age declined by an average of 0.12 glycan years per month of treatment over up to 15 months.
• Therapeutic plasma exchange (TPE): In nine participants undergoing monthly TPE over six months, glycan age decreased by an average of 0.4 glycan years per month. This provides quantitative data suggesting that physically removing and replacing circulating factors rejuvenates the IgG glycome.
• Caloric restriction: In the DIOGENES intervention (680 participants on an 800 kcal/day diet for eight weeks), an average weight loss of 11 kg was associated with a statistically significant deceleration of glycan aging.

Figure 1. Three interventions were associated with a younger glycan profile. GlycanAge decreased during hormone replacement therapy (A) and therapeutic plasma exchange (B), and was modestly reduced following eight weeks of caloric restriction and weight loss (C).

These three mechanisms (hormonal restoration, systemic clearance, and metabolic restriction) all resulted in a directional shift toward a younger glycan profile. This convergence confirms that the glycome is a dynamic readout of systemic biological state, capable of moving in both directions.

Implications for the Future of Health Management

Collectively, these findings reframe the utility of biological aging tests. While conventional diagnostics detect conditions after a clinical threshold is crossed, the glycome offers a measure of cumulative inflammatory pressure that precedes those conditions.

First, it identifies shared biology. The underlying immune drift appears consistent across varied conditions, suggesting that treating the root cause of "inflammaging" could have broad, multi-disease benefits.

Second, it provides independent predictive value. It does not simply restate what kidney function, blood pressure, or cholesterol already reveal; it adds critical information regarding long-term immunological wear.

Third, it is highly actionable. Because it responds to individual-level interventions on timescales of months, it provides clinicians and patients with a feedback loop to measure the efficacy of lifestyle and medical protocols.